...
【24h】

Early adjuvant radiotherapy in the treatment of atypical meningioma

机译:早期佐剂放射治疗非典型脑膜瘤

获取原文
获取原文并翻译 | 示例
           

摘要

Atypical meningiomas have a greater propensity to recur than benign meningiomas and the benefits of early adjuvant radiotherapy are unclear. Existing studies report conflicting results. This retrospective cohort study evaluated the role of early adjuvant radiotherapy following surgical resection of atypical meningioma. A triple center case-note review of adults with newly-diagnosed atypical meningiomas between 2001 and 2010 was performed. Pathology diagnosis was made according to the World Health Organization classification in use at the time of surgery. Patients with multiple meningiomas, neurofibromatosis type 2 and radiation-induced meningiomas were excluded. Extent of resection was defined as gross total resection (GTR; Simpson Grade I-III) or subtotal resection (STR; Simpson Grade IV-V). Survival analysis was performed using the Kaplan-Meier method. One hundred thirty-three patients were identified with a median age of 62 years (range 22-86 years) and median follow-up of 57.4 months (range 0.1-152.2 months). Tumors were mostly located in the convexity (50.4%) or falcine/parasagittal regions (27.1%). GTR (achieved in 85%) was associated with longer progression free survival (PFS) (5 year PFS 81.2% versus 40.08%, log-rank = 11.117, p = 0.001) but not overall survival (OS) (5 year OS 76.6% versus 39.7%, log-rank = 3.652, p = 0.056). Following GTR, early adjuvant radiotherapy was administered to 28.3% of patients and did not influence OS (5 year OS 77.0% versus 75.7%, log-rank = 0.075, p = 0.784) or PFS (5 year PFS 82.0% versus 79.3%, log-rank = 0.059, p = 0.808). Although extent of resection emerged as an important prognostic variable, early adjuvant radiotherapy did not influence outcome following GTR of atypical meningiomas. Prospective randomized controlled trials are planned. (C) 2015 Elsevier Ltd. All rights reserved.
机译:非典型脑膜瘤比良性脑膜瘤的重复倾向,早期佐剂放射治疗的益处尚不清楚。现有研究报告了相互矛盾的结果。该回顾性队列研究评估了早期佐剂放射治疗在非典型脑膜瘤外科切除后的作用。在2001年至2010年间,对具有新诊断的非典型脑膜瘤的成人的三重案件 - 注意审查。病理学诊断是根据在手术时使用的世界卫生组织分类进行的。排除了多种脑膜瘤,神经纤维瘤病型和辐射诱导的脑膜瘤的患者。切除程度被定义为总分解粗糙(GTR; SIMPSON等级I-III)或小次切除(SIMPSON级IV-V)。使用Kaplan-Meier方法进行存活分析。鉴定了一百三十三名患者,中位年龄为62岁(22-86岁),中位随访57.4个月(范围0.1-152.2个月)。肿瘤大部分位于凸起(50.4%)或镰刀/放射性区域(27.1%)。 GTR(85%达到85%)与较长的进展免费存活(PFS)(5年PFS 81.2%对40.08%,Log-Rank = 11.117,P = 0.001)但不是总体生存(OS)(5年OS 76.6%与39.7%,log-andal = 3.652,p = 0.056)。在GTR之后,将早期佐剂放射治疗施用至28.3%的患者,并且不影响OS(5年OS 77.0%,对数= 0.075,P = 0.784)或PFS(5年PFS 82.0%与79.3% log-rank = 0.059,p = 0.808)。虽然切除程度被出现为重要的预后变量,但早期的佐剂放射疗法不会影响非典型脑膜瘤的GTR后的结果。计划预期随机对照试验。 (c)2015 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号